Idiopathic Pulmonary Fibrosis News and Research

RSS

Pulmonary fibrosi is a condition in which tissue deep in your lungs becomes thick and stiff, or scarred, over time. The development of the scarred tissue is called fibrosis. As the lung tissue becomes thicker, your lungs lose their ability to move oxygen into your bloodstream. As a result, your brain and other organs don't get the oxygen they need.

In some cases, doctors can find out what's causing the fibrosis. But in most cases, they can't find a cause. They call these cases idiopathic pulmonary fibrosis (IPF). IPF is a serious condition. About 200,000 Americans have it. About 50,000 new cases are diagnosed each year. IPF mostly affects people who are 50 to 75 years of age. IPF varies from person to person. In some people, the lung tissue quickly becomes thick and stiff. In others, the process is much slower. In some people, the condition stays the same for years. IPF has no cure yet. Many people live only about 3 to 5 years after diagnosis. The most common cause of death related to IPF is respiratory failure.

New findings from a safety and feasibility clinical trial on removal of senescent cells

Mayo Clinic researchers, along with collaborators from Wake Forest School of Medicine and the The University of Texas Health Sciences Center at San Antonio, have published findings from a safety and feasibility clinical trial on the removal of senescent cells from a small group of patients with pulmonary fibrosis

7 Jan 2019

MUSC researchers identify potential therapeutic target for lung fibrosis

In an article published online by Frontiers in Endocrinology, researchers at the Medical University of South Carolina report that they have identified a potential therapeutic target for lung fibrosis or scarring.

19 Dec 2018

Researchers identify link between mucus in the small airways and pulmonary fibrosis

A team of investigators led by members of the University of Colorado School of Medicine faculty at CU Anschutz Medical Campus has identified a connection between mucus in the small airways and pulmonary fibrosis.

18 Dec 2018

Middle-aged adults with lung disease may have greater risk of dementia later in life

Middle-aged adults with lung disease may be at greater risk of developing dementia or cognitive impairment later in life, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

26 Nov 2018

Researchers identify common genetic connection in lung conditions

An international research team led by members of the University of Colorado School of Medicine faculty has identified a genetic connection between rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.

22 Oct 2018

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

8 Oct 2018

Study reveals long-term safety, efficacy of Ofev in patients with idiopathic pulmonary fibrosis

Results from INPULSIS-ON, published today in Lancet Respiratory Medicine, provide insights into the long-term safety, efficacy, and tolerability of Ofev (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF).

17 Sep 2018

Cedars-Sinai receives $12 million from NIH to investigate deadly lung conditions

A scientific team led by Cedars-Sinai has been awarded $12 million from the National Institutes of Health to investigate two deadly lung conditions: idiopathic pulmonary fibrosis and chronic lung allograft dysfunction.

11 Sep 2018

UA researchers receive $4.4 million grant to focus on idiopathic pulmonary fibrosis

Scar tissue is a good thing. When you fall and scrape your knee, the natural process jumps into gear, sealing up wounds and healing damaged tissue.

6 Sep 2018

New guideline developed to help physicians diagnose idiopathic pulmonary fibrosis

A new international guideline has been developed to help physicians diagnosis idiopathic pulmonary fibrosis, a rare and often fatal lung disease whose cause is unknown.

31 Aug 2018

UAB receives NIH grant to continue evaluation of new medication for IPF

The University of Alabama at Birmingham has received a grant from the National Institutes of Health totaling $8.9 million to fund a multiyear program evaluating the role of a new medication in a clinical trial for patients suffering from idiopathic pulmonary fibrosis

24 Aug 2018

Scleroderma Foundation names Tulane professor as 'Doctor of the Year'

Dr. Lesley Ann Saketkoo, an associate professor of clinical medicine at Tulane University School of Medicine, has been named Doctor of the Year by the Scleroderma Foundation. The award recognizes leadership and commitment to the community battling scleroderma, a disabling and life-limiting multi-organ autoimmune disease with progressive lung, heart, kidney, gastrointestinal tract and/or vascular involvement.

21 Aug 2018

Gene therapy with telomerase does not increase cancer risk, study shows

Negative results and findings in science are perhaps less newsworthy, but they are no less important. Particularly when, as in this case, they demonstrate that a possible new therapeutic pathway against idiopathic pulmonary fibrosis and other diseases associated to short telomeres is in fact safe.

21 Aug 2018

Penn researchers develop first mouse model of idiopathic pulmonary fibrosis

The biggest hurdle to finding effective therapies for idiopathic pulmonary fibrosis (IPF) – a life-threatening condition in which the lungs become scarred and breathing is increasingly difficult – has been the inability to fully model the disease in animals, limiting the ability to observe and understand the disease.

16 Aug 2018

Scientists uncover mechanisms responsible for development of fibrosis

Idiopathic pulmonary fibrosis is an incurable lung disease of unknown origin with limited treatment options. Research suggests that the signaling molecule WNT5A plays a key role in the pathogenic process.

10 Aug 2018

Established lung fibrosis can be reversed using diabetes drug treatment

Researchers at the University of Alabama at Birmingham have shown -; for the first time -; that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.

2 Jul 2018

Researchers identify culprit that spurs damaging inflammation following heart attack

Scientists have zeroed in on a culprit that spurs damaging inflammation in the heart following a heart attack. The guilty party is a type of immune cell that tries to heal the injured heart but instead triggers inflammation that leads to even more damage.

8 Jun 2018

Idiopathic Pulmonary Fibrosis News and Research

Further Reading